Melphalan Hydrochloride
Brand Names: Melphalan Hydrochloride Generic
Methodology & AI Transparency ⓘ
Melphalan Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
- 2 Real-world patient consensus: Tracked across 8 patient dosage logs with a 90% satisfaction benchmark (RxCUI 311487).
- 3 Typical cash cost range: Public pharmacy ledger: $32.80 low cash benchmark vs. $80.36 chain retail average ($0.6000/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Melphalan Hydrochloride tolerability events: nausea (9.4%), headache (7.5%), dizziness (5.3%).
Ask our AI Specialists anything about Melphalan Hydrochloride
Melphalan Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
CLINICAL PHARMACOLOGY Melphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N 7 position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells. Pharmacokinetics Following injection, drug plasma concentrations declined rapidly in a biexponential manner with distribution phase and terminal elimination phase half-lives of approximately 10 and 75 minutes, respectively.
Pharmacokinetic profiling of Melphalan Hydrochloride demonstrates an elimination half-life of Terminal t½ estimated at 4–10 hrs depending on renal/hepatic reserve (Melphalan Hydrochloride) with F ≈ 47%–59% systemic availability after standard oral Melphalan Hydrochloride administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across melphalan hydrochloride regimens, reaching clinical onset within time to peak concentration spans 1 to 2 hrs under melphalan hydrochloride maintenance.
Titration schedules for Melphalan Hydrochloride (Kit → 16 mg → 50% → 30 mg) require excluding contraindications melphalan hydrochloride for injection should not be used in patients whose disease has demonstrated prior resistance to this agent.; patients who have demonstrated hypersensitivity to melphalan hydrochloride for injection should not be given the drug.; real-world patient logs highlight nausea (9.4% of reports), headache (7.5% of reports), dizziness (5.3% of reports) alongside a 90.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Melphalan Hydrochloride (fda prescription therapeutic agent).
Botanical enzyme modulators may alter oral first-pass exposure of Melphalan Hydrochloride; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Melphalan hydrochloride for injection should not be used in patients whose disease has demonstrated prior resistance to this agent.
- Patients who have demonstrated hypersensitivity to melphalan hydrochloride for injection should not be given the drug.
Logged Side-Effect Incidence (8 Reports)
Melphalan Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Melphalan Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Health-related quality of life with daratumumab, bortezomib, melphalan, and Significant improvements were observed with D-VMP versus VMP in Global Health Status (GHS) score at 9 months (p = 0.0443) and in social functioning and nausea and vomiting symptom scores at 12 months (p = 0.0042 and p =... Annals of hematology • 2025-05-15 • Phase III Randomized Trial | N = 146 | 82/100 | PMID 40407887 ↗ |
| Can This Approach Help? Inside the Latest Research on Isolated liver Perfusion With Melphalan for Patients With Isolated Uveal Melanoma IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2023-06-01 • Phase III Randomized Trial | N = 43 | 82/100 | PMID 36940407 ↗ |
Melphalan Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6000/unit (~$18.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $80.36 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $32.80 / mo | View logs ↓ |
Melphalan Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Melphalan Hydrochloride RxNorm Concept ID | 311487 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $80.36 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $32.80 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Melphalan Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Melphalan Hydrochloride integrating DailyMed SPL (2018-04-10), CMS NADAC ($0.6000/unit), and 8 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Melphalan Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.